Oncimmune Regulatory News (ONC)

23 September 2020

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Oncimmune to profile samples from Genentech's rheumatology clinical trials

New contract further demonstrates Oncimmune's expanding global footprint for ImmunoINSIGHTS

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, today announces that it has signed a collaboration with Genentech, a member of the Roche Group, to characterise the autoantibody profiles of patients in clinical trials for rheumatological diseases, including Systemic Lupus Erythematosus (SLE).

In this new project, Oncimmune will use its proprietary NavigAID™ panel to characterise autoantibody profiles from trial participants.

Following completion of this project, Genentech has the option to expand the contract to profile additional samples.

SLE is a chronic, incurable autoimmune disease associated with multiple symptoms that can flare up over time. Diagnosis of SLE can be challenging. An objective of the project includes better characterisation of the disease, where there is a high unmet need for an effective therapy.

This project builds upon Oncimmune's broadening commercial footprint to not only deliver diagnostic tests, through EarlyCDT Lung and Liver, but also to partner with large pharmaceutical companies by profiling autoantibodies and developing commercial companion diagnostic tests through Oncimmune's ImmunoINSIGHTS service business.

Dr Adam M Hill, CEO of Oncimmune said: "Genentech is a pre-eminent biotechnology company, considered a leader in the biotech industry today. This contract adds to the already substantial pipeline of contracted revenue through our ImmunoINSIGHTS business in FY2021 and provides another opportunity to show how our NavigAID™ technology can assist partners in increasing their ability to better assess where their medicines could make an impact. We look forward to delivering this project and contributing to the scientific understanding of lupus."

For further information:

Oncimmune Holdings plc

Adam Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

contact@oncimmune.co.uk

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Daniel Harris, Victoria Ayton

+44 (0)20 3829 5000

N+1 Singer (Joint Broker)

Aubrey Powell, Harry Gooden, Iqra Amin, James Fischer

+44 (0)20 7496 3000

WG Partners (Joint Broker)

David Wilson, Chris Lee

+44 (0)203 705 9321

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

Oncimmune@fticonsulting.com

+44 (0)20 3727 1000

About Oncimmune

Our intimate understanding of the human immune system enables us to harness its sophisticated response to disease to detect cancer earlier and to support the development of better therapies.

The key to improving cancer survival is early detection and better selection for therapy. As a company, we are driven by our passion to improve cancer survival and give people extra time. Oncimmune's immunodiagnostic test, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis.

The unique combination of our core technology and understanding of the immune system, powers our ImmunoINSIGHTS service; a proprietary platform that enables life science organisations to optimise drug development and delivery, leading to more effective, targeted as well as safer treatments for patients.

Oncimmune was founded in 2002 and launched its platform diagnostic technology in 2009, followed by the launch of its first commercial tests, EarlyCDT Lung and EarlyCDT Liver. To date, over 200,000 tests have been performed for patients worldwide. EarlyCDT Lung was also used in what is believed to be the largest randomised controlled trial for the early detection of lung cancer using biomarkers, the successful National Health Service (NHS) Early detection of Cancer of the Lung ("ECLS") trial of 12,208 high-risk smokers in Scotland. This trial demonstrated that EarlyCDT Lung reduced the incidence of patients with late-stage lung cancer or unclassified presentation at diagnosis, compared to standard clinical practice.

Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and a partner representative office in Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

What is NavigAID?

Oncimmune's NavigAID arrays are thoroughly validated containing well defined antigen panels, largely encompassing markers of interest for each of the disease types being investigated.

Our portfolio of panels includes out-of-the-box NavigAID arrays for immuno-oncology and autoimmune diseases. These validated panels are frequently used as the starting point for collaborations with partners to add further markers of interest to their specific therapy and its specific indication.